Abstract
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been established as promising targets for cancer treatment. Therapeutics targeting TRAIL and its receptors are not only effective in killing many types of tumors, but they also synergize with traditional therapies and show efficacy against tumors that are otherwise resistant to conventional treatments. We describe here the identification and characterization of two human monoclonal antibodies, m921 and m922, that are specific for human DR4. Both antibodies competed with TRAIL for binding to DR4, but only m921 recognized cell surface-associated DR4 and inhibited the growth of ST486 cells. This antibody may have potential for further development as a candidate therapeutic and research tool.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, N.I.H., Intramural
MeSH terms
-
Animals
-
Antibodies, Monoclonal / genetics
-
Antibodies, Monoclonal / metabolism
-
Antibodies, Monoclonal / pharmacology*
-
CHO Cells
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cell Survival / drug effects
-
Cricetinae
-
Cricetulus
-
Dose-Response Relationship, Drug
-
Humans
-
Immunoglobulin Fab Fragments / genetics
-
Immunoglobulin Fab Fragments / metabolism
-
Immunoglobulin Fab Fragments / pharmacology
-
Peptide Library
-
Protein Binding / drug effects
-
Receptors, TNF-Related Apoptosis-Inducing Ligand / agonists*
-
Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics
-
Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism
-
Recombinant Proteins / agonists
-
Recombinant Proteins / immunology
-
TNF-Related Apoptosis-Inducing Ligand / metabolism
-
TNF-Related Apoptosis-Inducing Ligand / pharmacology
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Peptide Library
-
Receptors, TNF-Related Apoptosis-Inducing Ligand
-
Recombinant Proteins
-
TNF-Related Apoptosis-Inducing Ligand